Search research articles
Contact Us
Filters
Showing results (61-70 of 580) with videos related to
Page
of 58
Sort By:
Future Virology
|
March 24, 2020
Development of SARS vaccines and therapeutics is still needed
Shibo Jiang, Lu Lu, Lanying Du
Frontiers in Immunology
|
January 13, 2018
Single-Domain Antibodies As Therapeutics against Human Viral Diseases
Yanling Wu, Shibo Jiang, Tianlei Ying
Signal Transduction and Targeted Therapy
|
November 30, 2023
SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread
Xinling Wang, Lu Lu, Shibo Jiang
Signal Transduction and Targeted Therapy
|
March 16, 2023
Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
Qiao Wang, Lujia Sun, Shibo Jiang
Current Pharmaceutical Design
|
April 12, 2002
Peptide and non-peptide HIV fusion inhibitors
Shibo Jiang, Qian Zhao, Asim K Debnath
Cellular & Molecular Immunology
|
February 7, 2020
A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome
Shibo Jiang, Shuai Xia, Tianlei Ying, et al.
Vaccines
|
September 2, 2020
Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines
Naru Zhang, Chaoqun Li, Shibo Jiang, et al.
Expert Opinion on Therapeutic Patents
|
January 12, 2017
Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015)
Wen Li, Lu Lu, Weihua Li, et al.
Frontiers in Cellular and Infection Microbiology
|
September 12, 2022
Corrigendum: Advancement in the development of therapeutics against Zika virus infection
Kangchen Li, Qianting Ji, Shibo Jiang, et al.
Biochemical and Biophysical Research Communications
|
November 9, 2004
Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry
Yuxian He, Yusen Zhou, Pamela Siddiqui, et al.
Page
of 58
Search research articles
Search
Showing results (61-70 of 580) with videos related to
Sort By:
Page
of 58
Future Virology
|
March 24, 2020
Development of SARS vaccines and therapeutics is still needed
Shibo Jiang, Lu Lu, Lanying Du
Frontiers in Immunology
|
January 13, 2018
Single-Domain Antibodies As Therapeutics against Human Viral Diseases
Yanling Wu, Shibo Jiang, Tianlei Ying
Signal Transduction and Targeted Therapy
|
November 30, 2023
SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread
Xinling Wang, Lu Lu, Shibo Jiang
Signal Transduction and Targeted Therapy
|
March 16, 2023
Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
Qiao Wang, Lujia Sun, Shibo Jiang
Current Pharmaceutical Design
|
April 12, 2002
Peptide and non-peptide HIV fusion inhibitors
Shibo Jiang, Qian Zhao, Asim K Debnath
Cellular & Molecular Immunology
|
February 7, 2020
A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome
Shibo Jiang, Shuai Xia, Tianlei Ying, et al.
Vaccines
|
September 2, 2020
Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines
Naru Zhang, Chaoqun Li, Shibo Jiang, et al.
Expert Opinion on Therapeutic Patents
|
January 12, 2017
Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015)
Wen Li, Lu Lu, Weihua Li, et al.
Frontiers in Cellular and Infection Microbiology
|
September 12, 2022
Corrigendum: Advancement in the development of therapeutics against Zika virus infection
Kangchen Li, Qianting Ji, Shibo Jiang, et al.
Biochemical and Biophysical Research Communications
|
November 9, 2004
Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry
Yuxian He, Yusen Zhou, Pamela Siddiqui, et al.
Page
of 58